Nurix Therapeutics Dirección

Dirección controles de criterios 4/4

El CEO de Nurix Therapeutics' es Arthur Sands , nombrado en Sep 2014, tiene una permanencia de 9.58 años. compensación anual total es $4.36M, compuesta por 13.5% salario y 86.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.52% de las acciones de la empresa, por valor de $3.81M. La antigüedad media del equipo directivo y de la junta directiva es de 4.2 años y 3.6 años, respectivamente.

Información clave

Arthur Sands

Chief Executive Officer (CEO)

US$4.4m

Compensación total

Porcentaje del salario del CEO	13.5%
Permanencia del CEO	9.6yrs
Participación del CEO	0.5%
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21

Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Apr 15

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Arthur Sands en comparación con los beneficios de Nurix Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Feb 29 2024	n/a	n/a	-US$145m
Nov 30 2023	US$4m	US$591k	-US$144m
Aug 31 2023	n/a	n/a	-US$149m
May 31 2023	n/a	n/a	-US$157m
Feb 28 2023	n/a	n/a	-US$179m
Nov 30 2022	US$9m	US$572k	-US$180m
Aug 31 2022	n/a	n/a	-US$171m
May 31 2022	n/a	n/a	-US$154m
Feb 28 2022	n/a	n/a	-US$135m
Nov 30 2021	US$5m	US$539k	-US$117m
Aug 31 2021	n/a	n/a	-US$99m
May 31 2021	n/a	n/a	-US$89m
Feb 28 2021	n/a	n/a	-US$63m
Nov 30 2020	US$17m	US$521k	-US$43m
Aug 31 2020	n/a	n/a	-US$37m
May 31 2020	n/a	n/a	-US$21m
Feb 29 2020	n/a	n/a	-US$24m
Nov 30 2019	US$1m	US$474k	-US$22m

Compensación vs. Mercado: La compensación total ($USD4.36M) de Arthur está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.44M).

Compensación vs. Ingresos: La compensación de Arthur ha sido consistente con los resultados de la empresa en el último año.

CEO

Arthur Sands (61 yo)

9.6yrs

Permanencia

US$4,363,120

Compensación

Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Arthur Sands	CEO, President & Director	9.6yrs	US$4.36m	0.52% $ 3.8m
Johannes Van Houte	Chief Financial Officer	8.1yrs	US$1.61m	0.12% $ 844.6k
Gwenn Hansen	Chief Scientific Officer	3.8yrs	US$1.63m	0.061% $ 449.9k
John Kuriyan	Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Michael Rapé	Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Arthur Weiss	Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Rita Kwong	Senior Accounting Manager	no data	sin datos	sin datos
Christine Ring	Chief Legal Officer	4.6yrs	US$1.65m	0.029% $ 215.4k
Eric Schlezinger	Chief People Officer	1.7yrs	sin datos	sin datos
Jason Kantor	Chief Business Officer	3.8yrs	sin datos	sin datos
Seema Rogers	VP & Head of Clinical Operations	4.7yrs	sin datos	sin datos
Christopher Phelps	Senior VP & Head of Early Drug Discovery	3.3yrs	sin datos	sin datos

4.2yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NRIX se considera experimentado (4.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Arthur Sands	CEO, President & Director	9.6yrs	US$4.36m	0.52% $ 3.8m
John Kuriyan	Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Michael Rapé	Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Arthur Weiss	Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Julia Gregory	Independent Director	4.7yrs	US$179.30k	0% $ 0
Ronald Levy	Member of Medical Advisory Board	1.3yrs	sin datos	sin datos
Judith Reinsdorf	Independent Director	2.5yrs	US$225.79k	0% $ 0
Roy Baynes	Member of Medical Advisory Board	no data	sin datos	sin datos
Lori Kunkel	Independent Director	4.8yrs	US$228.29k	0.091% $ 667.8k
David Lacey	Independent Chairman	8yrs	US$202.55k	0.056% $ 412.0k
Paul Silva	Independent Director	2.5yrs	US$165.72k	0% $ 0
Edward Saltzman	Independent Director	1.6yrs	US$555.64k	0% $ 0

3.6yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NRIX se considera experimentada (3.6 años de antigüedad promedio).

Nurix Therapeutics Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Appoints Edward C. Saltzman to its Board of Directors

Nurix Therapeutics, Inc. Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Chief Financial Officer exercised options to buy US$621k worth of stock.

Recent updates

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial

Price target decreased by 9.4% to US$24.09

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Chief Financial Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc. Announces Publication in the Journal Science Identifying A New Class of Btk Mutations That Are Susceptible to Nx-2127, A Novel Btk and Ikzf1/3 Degrader

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Chief Financial Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Presents Positive Clinical Data from its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, Nx-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics, Inc. Announces Partial Clinical Hold for Nx-2127 Phase 1 Trial

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Plans to Initiate Two New Phase 1b Dose Expansion Cohorts in Ongoing Phase 1a/1b Clinical Trial of NX-2127 in Patients with Relapsed or Refractory B-Cell Malignancies

Consensus revenue estimates increase by 39%

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 23%, EPS upgraded

Price target decreased by 7.7% to US$31.45

Full year 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Price target decreased to US$34.91

Nurix Announces Initial Nx-1607 Phase 1 Data Presented At the 37Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc) Demonstrating Targeted Cbl-B Inhibition in Patients with Advanced Malignancies

Nurix Therapeutics Inc. Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation Summit

Price target decreased to US$34.91

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Nurix Therapeutics, Inc. Appoints Edward C. Saltzman to its Board of Directors

Nurix Therapeutics, Inc. Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Price target decreased to US$38.20

Price target decreased to US$38.80

Nurix Therapeutics, Inc. has announced a Derivatives Offering in the amount of $54.996046 million.

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Nurix Therapeutics, Inc. Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Nurix Therapeutics, Inc.(NasdaqGM:NRIX) dropped from Russell 2000 Growth Index

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs At the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Chief Financial Officer exercised options to buy US$621k worth of stock.

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

Nurix Therapeutics, Inc. Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948

High number of new directors

Nurix Therapeutics, Inc. Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

Nurix Therapeutics Receives Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

Nurix Therapeutics, Inc. Announces Resignation of Jeffrey K. Tong as Class II Member of the Board and as a Member of the Board's Audit Committee and Compensation Committee

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Price target decreased to US$47.33

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

Chief Scientific Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of Nx-5948